ENOV Quote, Financials, Valuation and Earnings

Globus Medical has a net margin of -10.02% compared to Enovis's net margin of 12.62%. Enovis's return on equity of -26.77% beat Globus Medical's return on equity of 4.59%.

Enovis has a consensus price target of $56.50, signalling upside risk potential of 68.96%. On the other hand Globus Medical has an analysts' consensus of $85.17 which suggests that it could grow by 42.92%. Given that Enovis has higher upside potential than Globus Medical, analysts believe Enovis is more attractive than Globus Medical.

Enovis has a beta of 1.583, which suggesting that the stock is 58.325% more volatile than S&P 500. In comparison Globus Medical has a beta of 1.324, suggesting its more volatile than the S&P 500 by 32.371%.

Enovis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

Enovis quarterly revenues are $558.8M, which are smaller than Globus Medical quarterly revenues of $598.1M. Enovis's net income of -$56M is lower than Globus Medical's net income of $75.5M. Notably, Enovis's price-to-earnings ratio is -- while Globus Medical's PE ratio is 44.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis is 0.87x versus 3.29x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

ICU Medical has a net margin of -10.02% compared to Enovis's net margin of -2.56%. Enovis's return on equity of -26.77% beat ICU Medical's return on equity of -4.64%.

Enovis has a consensus price target of $56.50, signalling upside risk potential of 68.96%. On the other hand ICU Medical has an analysts' consensus of $186.20 which suggests that it could grow by 42.75%. Given that Enovis has higher upside potential than ICU Medical, analysts believe Enovis is more attractive than ICU Medical.

Enovis has a beta of 1.583, which suggesting that the stock is 58.325% more volatile than S&P 500. In comparison ICU Medical has a beta of 0.870, suggesting its less volatile than the S&P 500 by 12.976%.

Enovis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ICU Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis pays -- of its earnings as a dividend. ICU Medical pays out -- of its earnings as a dividend.

Enovis quarterly revenues are $558.8M, which are smaller than ICU Medical quarterly revenues of $604.7M. Enovis's net income of -$56M is lower than ICU Medical's net income of -$15.5M. Notably, Enovis's price-to-earnings ratio is -- while ICU Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis is 0.87x versus 1.32x for ICU Medical. Usually stocks with elevated PS ratios are considered overvalued.

Integer Holdings has a net margin of -10.02% compared to Enovis's net margin of -5.14%. Enovis's return on equity of -26.77% beat Integer Holdings's return on equity of 4.85%.

Enovis has a consensus price target of $56.50, signalling upside risk potential of 68.96%. On the other hand Integer Holdings has an analysts' consensus of $148.75 which suggests that it could grow by 22.3%. Given that Enovis has higher upside potential than Integer Holdings, analysts believe Enovis is more attractive than Integer Holdings.

Enovis has a beta of 1.583, which suggesting that the stock is 58.325% more volatile than S&P 500. In comparison Integer Holdings has a beta of 1.030, suggesting its more volatile than the S&P 500 by 3.045%.

Enovis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis pays -- of its earnings as a dividend. Integer Holdings pays out -- of its earnings as a dividend.

Enovis quarterly revenues are $558.8M, which are larger than Integer Holdings quarterly revenues of $437.4M. Enovis's net income of -$56M is lower than Integer Holdings's net income of -$22.5M. Notably, Enovis's price-to-earnings ratio is -- while Integer Holdings's PE ratio is 57.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis is 0.87x versus 2.45x for Integer Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -10.02% compared to Enovis's net margin of 0.18%. Enovis's return on equity of -26.77% beat Xtant Medical Holdings's return on equity of -26.62%.

Enovis has a consensus price target of $56.50, signalling upside risk potential of 68.96%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 156.6%. Given that Xtant Medical Holdings has higher upside potential than Enovis, analysts believe Xtant Medical Holdings is more attractive than Enovis.

Enovis has a beta of 1.583, which suggesting that the stock is 58.325% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.124, suggesting its less volatile than the S&P 500 by 112.425%.

Enovis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Enovis quarterly revenues are $558.8M, which are larger than Xtant Medical Holdings quarterly revenues of $32.9M. Enovis's net income of -$56M is lower than Xtant Medical Holdings's net income of $58K. Notably, Enovis's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis is 0.87x versus 0.76x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.